KLRK1 and neoplasm: The upregulation of MHC-I molecules, Fas, and natural killer group 2 member D (NKG2D) on residual tumor cells in response to higher doses of RT allows recognition by incoming T-cells, with subsequent release of effector cytokines and killing of tumor targets (4).